title: Shutdown of immunological priming and presentation after in vivo administration of adenovirus.
abstract: Adenoviral (Adv) vectors are widely used in both experimental and clinical trials for vaccination and gene therapy. Recombinant Adv can evoke potent innate immune responses and adaptive immune responses to encoded antigens. However, how Adv infection affects the response to subsequently encountered antigens is poorly understood. We show that intravenously administered replication defective (E1 and E3 deleted) Adv educes functional changes in dendritic cells (DC) resulting in impaired priming of cytotoxic T lymphocytes (CTL) more than 7 days after Adv treatment. Generalized DC activation was indicated by transient upregulation of CD86 and reduced endocytosis of fluorescent beads. It is known that CD8+ DC are predominantly responsible for uptake and presentation (cross-presentation) of exogenous antigens to CD8+ CTL. Hence, impaired endocytosis in CD8+, but not CD8-, DC at 7 days after Adv administration provided an explanation for the impaired CTL response to antigen at this time. Shutdown of cross-presentation was confirmed using cytochrome c (cytc), an agent that selectively depletes cross-presenting DC. Adv-infection rendered CD8+ DC resistant to depletion by cytc. As the cross-presentation pathway underlies CD8 T-cell responses to many cancers and to vaccines or viruses that do not directly infect DC, systemic Adv administration may impair these responses.
authors.affiliation: The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. sutherland@wehi.edu.au
authors.forename: R M
authors.initials: RM
authors.lastname: Sutherland
authors.forename: S L
authors.initials: SL
authors.lastname: Londrigan
authors.forename: J L
authors.initials: JL
authors.lastname: Brady
authors.forename: H
authors.initials: H
authors.lastname: Azher
authors.forename: E M
authors.initials: EM
authors.lastname: Carrington
authors.forename: Y
authors.initials: Y
authors.lastname: Zhan
authors.forename: J
authors.initials: J
authors.lastname: Vega-Ramos
authors.forename: J A
authors.initials: JA
authors.lastname: Villadangos
authors.forename: A M
authors.initials: AM
authors.lastname: Lew
mesh_terms: D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology*; D000818:Animals; D017951:Antigen Presentation; D045142:Cross-Priming; D003713:Dendritic Cells / Q000276:immunology; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy; D008213:Lymphocyte Activation; D018655:Lymphocyte Count; D051379:Mice; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology